Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

Article ID	Journal	Published Year	Pages	File Type
6063748	Journal of Allergy and Clinical Immunology	2015	16 Pages	PDF

Abstract

BI 655066 was well tolerated and associated with rapid, substantial, and durable clinical improvement in patients with moderate-to-severe psoriasis, supporting a central role for IL-23 in psoriasis pathogenesis.

Keywords

AUEC DC-LAMP Emax MACE SAE sPGA TIA RNA-seq mAb static Physician Global Assessment PASI RNA sequencing Randomized fold change maximum effect transient ischemic attack major adverse cardiovascular event Single dose adverse event Serious adverse event Pharmacokinetics psoriasis area and severity index Biomarkers Psoriasis

Related Topics

Life Sciences Immunology and Microbiology Immunology

Preview

Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

Authors

James G. MD, PhD, Laura K. MD, Alan MD, Frank MD, Alexander MD, Sudha PhD, Bojan PhD, Stella MD, Elaine E.L. MD, David PhD, Alan MD, Steven MD, Paul MB BChir,